-
Australia Opens The Door for SKY-0515: Skyhawk Seeks Provisional Approval for Its Oral HD Drug
Latest News
-
The road ahead for uniQure: FDA says more data needed for AMT-130 gene therapy
⏱️ 10 min read | The FDA wants more data before approving AMT-130 for Huntington’s disease in the U.S. On March 2026, uniQure shared in an update that current Phase 1/2 data weren’t enough for the agency. A new randomized, sham-controlled trial may be required.
-
HD World Congress 2011: a retrospective
HDBuzz looks back at the highlights of the Huntington's disease world congress 2011 in Melbourne
-
HDAC inhibitors and a possible 'blood biomarker'
HDAC inhibitors explained, plus how new HDAC-related Huntington's disease research might help us find biomarkers
-
HD just got cilia
Huntington's disease just got cilia: huntingtin protein affects tiny but important hairs on cells called cilia
-
Gene silencing takes a targeted step forward
Targeting the mutant Huntington's disease gene for silencing, while leaving the healthy gene untouched
-
Prana Biotech's new trial of PBT2 in Huntington's disease: the lowdown
Prana Biotech's PBT2 trial in Huntington's disease: what we know so far & what copper has to do with the mutant prote
-
Oz Buzz Video: Day 2
The final day of Oz Buzz: the nightly news, interviews and features presentation from the HD World Congress 2011
-
Oz Buzz Video: Day 1
Day 1 of Oz Buzz: the nightly news, interviews and features presentation from the HD World Congress 2011
-
Oz Buzz Updates: Day 3
Day 3 of our coverage of the Huntington's disease World Congress 2011 in Melbourne
-
Oz Buzz Updates: Day 2
Day 2 of our coverage of the Huntington's disease World Congress 2011 in Melbourne
-
Oz Buzz Updates: Day 1
Day 1 of our coverage of the Huntington's disease World Congress 2011 in Melbourne
HDBuzz Trial Tracker
Progress update for NCT06585449 – A Study to Evaluate ALN-HTT02
Additional insights from Phase 2 study results and update on plans for Phase 3 trial for votoplam
